An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in the USA and EU for advanced melanoma, NSCLC, and RCC, and relapsed Hodgkin lymphoma in the USA. Programmed death-ligand 1 (PD-L1), a PD-1 ligand, is expressed on mononuclear leukocytes, myeloid cells, and tumor cells. PD-L1 is being investigated as a potential biomarker to predict the association of tumor PD-L1 expression with nivolumab efficacy.



Bristol-Myers Squibb and Dako previously reported on an automated PD-L1 immunohistochemical (IHC) assay that detects cell surface PD-L1 in formalin-fixed, paraffin-embedded, human tumor tissue specimens using Dako's Autostainer Link 48. The primary antibody for this assay is a rabbit monoclonal antihuman PD-L1 antibody, clone 28-8. Another rabbit monoclonal antihuman PD-L1 antibody, clone E1L3N, was compared with 28-8 for specificity and sensitivity using an identical detection method followed by vendor-recommended detection methods.



Using PD-L1 null clones of L2987 and ES-2 tumor cell lines, both antibodies were specific for detection of PD-L1 on the plasma membrane, although E1L3N also stained cytoplasm in ES-2 knockout cells. Using the identical method, E1L3N was slightly more sensitive than 28-8 based on staining intensities. Using manufacturer-recommended detection methods and predefined scoring criteria for plasma membrane staining of tumor and immune cells, 28-8 demonstrated significantly improved detection compared with E1L3N.



Epitope retrieval and highly sensitive detection reagents are key determinants in IHC detection of PD-L1.
Clinical Histochemistry, Clinical Translational Technologies & Operations, Bristol-Myers Squibb Company, LVL-H4.427B, Route 206 and Province Line Rd, Princeton, NJ, 08543, USA. john.cogswell@bms.com.
John
J
Cogswell
Clinical Histochemistry, Clinical Translational Technologies & Operations, Bristol-Myers Squibb Company, LVL-H4.427B, Route 206 and Province Line Rd, Princeton, NJ, 08543, USA.
H David
HD
Inzunza
Clinical Histochemistry, Clinical Translational Technologies & Operations, Bristol-Myers Squibb Company, LVL-H4.427B, Route 206 and Province Line Rd, Princeton, NJ, 08543, USA.
Qiuyan
Q
Wu
Clinical Histochemistry, Clinical Translational Technologies & Operations, Bristol-Myers Squibb Company, LVL-H4.427B, Route 206 and Province Line Rd, Princeton, NJ, 08543, USA.
John N
JN
Feder
Clinical Histochemistry, Clinical Translational Technologies & Operations, Bristol-Myers Squibb Company, LVL-H4.427B, Route 206 and Province Line Rd, Princeton, NJ, 08543, USA.
Gabe
G
Mintier
Clinical Histochemistry, Clinical Translational Technologies & Operations, Bristol-Myers Squibb Company, LVL-H4.427B, Route 206 and Province Line Rd, Princeton, NJ, 08543, USA.
James
J
Novotny
Duke University Medical Center, Durham, NC, USA.
Diana M
DM
Cardona
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000494:pharmacology; D000918:Antibody Specificity; D060890:B7-H1 Antigen / Q000302:isolation & purification*; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism; D045744:Cell Line, Tumor; D000939:Epitopes / Q000737:chemistry; D005819:Genetic Markers; D006801:Humans; D007150:Immunohistochemistry; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism; D000077594:Nivolumab; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; D000939:Epitopes; D005819:Genetic Markers; D000077594:Nivolumab
Tumori. 2012 Nov;98(6):751-5
23389362
Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-9
26317305
Cancer. 2011 May 15;117(10):2192-201
21523733
N Engl J Med. 2012 Jun 28;366(26):2443-54
22658127
Clin Cancer Res. 2005 Apr 15;11(8):2947-53
15837746
JAMA Oncol. 2016 Jan;2(1):46-54
26562159
J Immunol. 2003 Feb 1;170(3):1257-66
12538684
Med Oncol. 2011 Sep;28(3):682-8
20373055
Clin Cancer Res. 2004 Aug 1;10(15):5094-100
15297412
J Exp Med. 2000 Oct 2;192(7):1027-34
11015443
Cancer. 2010 Apr 1;116(7):1757-66
20143437
Nat Med. 1999 Dec;5(12):1365-9
10581077
Clin Lung Cancer. 2013 Mar;14(2):157-63
22868219
Lab Invest. 2014 Jan;94(1):107-16
24217091
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
24714771
Sci Transl Med. 2012 Mar 28;4(127):127ra37
22461641
Nat Med. 2002 Aug;8(8):793-800
12091876